• Login
    • Advanced search
    • Title
    • Channel
    • Module
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transport and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
Hogan Lovells Engage 5.7.7
      • Title
      • Channel
      • Module
    • Hit ENTER to search in content
    • Advanced search
    • Login
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transport and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
  1. News
  2. Product Safety: REACH considerations and Cosmetics Regulation

Product Safety: REACH considerations and Cosmetics Regulation

10 January 2022
    • Share by email
    • Share on
    • Twitter
    • LinkedIn
    • Get link
    • Get QR Code
    • Download
    • Print

Cosmetic ingredients and animal testing - manufacturer juggling with REACH and Cosmetics Regulation.

Since 11 July 2013 Article 18 of the Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products ("Cosmetics Regulation") bans animal testing for the safety assessment of cosmetic products or of its ingredients if alternative validated testing methods are available. A violation of this prohibition not only results in the product not being marketable in the European Union, but the manufacturer could also commit an offense or a misdemeanour. (Depending on Member States’ national provisions; in Germany it is for example a regulatory offence to put such products into circulation, punishable by a fine up to EUR 20,000).

This being said, manufacturers of cosmetic products may need to perform animal testing to comply with the requirements of the REACH Regulation (Regulation (EC) No 1907/2006), entered into force on 1 June 2007, (1) if the cosmetic ingredient is used not solely for cosmetics, but for other industries as well and therefore fall under the REACH Regulation as well or (2) if the ingredient is used solely for cosmetics, but to assess the risks to workers exposed to the ingredient during manufacturing, formulation, packaging etc. under the REACH Regulation.

This divergence often leads to a dilemma for manufacturers if they want to put their products onto the market without animal testing and who may even want to advertise their products being completely animal test free.

A recently published analysis shows, that registrants of REACH dossiers for chemicals with cosmetics as only reported use, used largely alternative testing methods, but some conducted even new in vivo tests to comply with REACH requirements (see Knight et al., Continuing Animal Tests on Cosmetic Ingredients for REACH in the EU, published 18 August 2021).

Manufacturers' juggling with REACH and Cosmetics Regulation has been evident at least since the Decision of the Board of Appeal of the European Chemicals Agency of 18 August 2020 (case number: A-010-2018). The appellant has unsuccessfully challenged a decision of ECHA demanding to submit information on certain toxicity studies in vivo for a substance (2-ethylhexyl salicylate), exclusively used as an ingredient in cosmetic products, in a registration dossier.

In its decision, the Board of Appeal of ECHA upheld the ECHA's understanding of the interface between REACH and Cosmetics regulations (see "Factsheet" of the ECHA of October 2014 on this topic). The European Commission in cooperation with the ECHA already clarified in 2014 the relationship between the Cosmetics Regulation and the REACH Regulation regarding substances exclusively used in cosmetics (All news - ECHA (europa.eu)). According to which, in summary "the testing and marketing bans in the Cosmetics Regulation do not apply to testing required for environmental endpoints, exposure of workers and non-cosmetic uses of substances under REACH. Registrants of substances registered exclusively for cosmetic use will still have to provide the required information under REACH wherever possible, by using alternatives to animal testing (such as computer modelling, read-across, weight of evidence etc.)."

In its decision, the Board of Appeal of the ECHA stated that "the REACH Regulation and the Cosmetics Regulation must (…) be interpreted and applied so that each is compatible and coherent with the other".

Comparing the intended purpose of the Cosmetics Regulation and the REACH Regulation becomes clear, that the REACH Regulation wants to cover all environmental risks that may arise from the product during its entire life cycle which includes especially workers during manufacturing, formulation and packaging of the product. Whereas the Cosmetics Regulation is aiming at the protection of the end user of the product.

In this context, it should be noted that the prohibitions in Article 18 of the Cosmetics Regulation apply if the animal tests are intended to demonstrate the safety of the cosmetic product or its ingredient for cosmetic use to meet the requirements of the Cosmetics Regulation (and the animal test is for example listed in the safety report). However, the prohibitions  in Article 18 do not already apply if the animal tests are only stated in the product information file and not in the safety report, as Article 11 of the Cosmetics Regulation stipulates that data on any animal testing performed by the manufacturer, his agents or suppliers, relating to the development or safety assessment of the cosmetic product or its ingredients, including any animal testing performed to meet the legislative or regulatory requirements of third countries should be included in the product information file (see judgment of the European Court of Justice of 21 September 2016, C-592/14).

Outlook

The position of the European Commission and the ECHA on the interface between REACH Regulation and Cosmetics Regulation seems clear. Manufacturers of cosmetics products will have to carefully consider how to respond to the challenge. New in vivo tests to comply with REACH requirements may be last resort if no alternative methods are validated/recognized by the Commission, ECHA or international bodies. But legal implications must be flagged.

To achieve the targeted goal that cosmetic products marketed in the European Union should be completely free of animal testing, the competent authorities and international bodies need to validate/develop alternative methods to animal testing where they are still lacking in the REACH Regulation. It is a start to validate alternative testing methods for the Cosmetics Regulation. However, one needs to validate alternative testing methods for the REACH Regulation and may need different testing methods as the two Regulations have different protection purposes and therefore may need different alternative methods to avoid animal testing. Of course those alternative methods need to be able to provide the same level of protection for the environment, the users and the workers.

 

 

Authored by Katrin Weixlgartner.

Contacts
Katrin Weixlgartner
Senior Associate
Munich
Keywords REACH, Cosmetic regulations, animal testing, Cosmetic Regulation and animal testing, ECHA
Languages English
Topics OTC Drugs and Cosmetics, Products Law
Countries Belgium, France, Germany, Hungary, Italy, Luxembourg, Netherlands, Poland, Spain, United Kingdom
Delete Comment ?

Are you sure want to delete comment ?

Get link
Embed
Share by email
Get QR Code

Scan this QR Code to share this content

  • Contact us
  • Disclaimer
  • Privacy
  • Cookies
  • Legal Notices
  • Terms of Use

 

This website is operated by Hogan Lovells International LLP, whose registered office is at Atlantic House, Holborn Viaduct, London, EC1A 2FG. For further details of Hogan Lovells International LLP and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2022 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.

Thomson Reuters HighQ Logo
© 2023 Hogan Lovells | Privacy Policy | Terms of Service